ADALIMUMAB

Brand name:

• Hulio®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa.

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (–)

Comment:

--

Submission sponsor:

Alphapharm Pty Ltd

Other PBAC consideration:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

21/02/2022

Lodgement of required documentation:

28/02/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 08/03/2022

Status:

Finalised

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---